Apollomics appoints Dr. Ya-Chi Huang to board following resignation

Apollomics appointed Dr. Ya‑Chi (Claudia) Huang to its board to replace Po‑Jen Hsueh (resigned Nov. 16, 2025) and named her to the Audit and Nominating & Corporate Governance committees, bringing the seven‑member board to five independent directors; Huang brings venture and biotech investment experience. The clinical‑stage oncology company, valued at roughly $46m, has seen APLM shares surge 40.1% over the past week and 338.65% over six months while trading at $21.45 (slightly below InvestingPro’s fair value) and advancing its lead c‑Met inhibitor vebreltinib (APL‑101) in Phase II. Crucially, Apollomics has terminated all U.S. employees including its CEO and CFO, will discontinue the SPARTA trial, is preparing a shareholder vote on a possible wind‑up, and will have its Nasdaq trading resumed on Oct. 15, 2025 — developments that point to acute liquidity and operational stress despite recent stock strength.

Analysis

Apollomics announced the appointment of Dr. Ya‑Chi (Claudia) Huang to the board effective Nov. 16, 2025, replacing Po‑Jen Hsueh and taking seats on the Audit and Nominating & Corporate Governance committees; the board now has seven members with five independents and Huang brings venture/biotech investment experience. The company is a clinical‑stage oncology developer with lead candidate vebreltinib (APL‑101) in Phase II and trades at $21.45, roughly in line but slightly below InvestingPro’s fair‑value estimate, after a one‑week gain of 40.1% and a six‑month rise of 338.65%.

Operational and financial stress signals are acute: Apollomics terminated all U.S. employees including its CEO and CFO, will discontinue the SPARTA trial, and is preparing a shareholder vote on a possible wind‑up, while InvestingPro data note the company has more cash than debt but is burning cash quickly and is valued at about $46 million. Nasdaq has scheduled resumptions of APLM and its warrants on Oct. 15, 2025 (warrants five minutes later), creating a likely liquidity event that may amplify price moves.

Market signals are highly negative (sentiment score −0.85; APLM −0.9) despite some analyst expectations for sales growth and an anticipated net‑income decline this year, suggesting the recent rally is driven by speculation rather than improved operational fundamentals. Key near‑term risks are the shareholder vote outcome, cash runway/solvency developments, any asset‑sale announcements, and increased volatility on trading resumption; governance additions provide limited mitigation against these existential risks.

Key Decisions for Investors

• Reduce or exit long positions given termination of U.S. staff, discontinuation of the SPARTA trial, and the pending shareholder vote on a possible wind‑up which materially increases downside risk
• If retaining exposure, size positions minimally and hedge (options where available) while actively monitoring cash runway disclosures, the shareholder vote timetable, and any asset‑sale or liquidation announcements
• Avoid initiating new longs ahead of Nasdaq trading resumption on Oct. 15, 2025 due to expected volatility and extremely negative sentiment; consider event‑driven short or hedged strategies only with active risk management